AcelRx Pharmaceuticals (ACRX) Reports In-Line Q3 Loss of 38c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts ACRX Hot Sheet
Join SI Premium – FREE
AcelRx Pharmaceuticals (NASDAQ: ACRX) reported Q3 EPS of ($0.38), in-line with the analyst estimate of ($0.38). Revenue for the quarter came in at $166 thousand versus the consensus estimate of $320 thousand.
For earnings history and earnings-related data on AcelRx Pharmaceuticals (ACRX) click here.
For earnings history and earnings-related data on AcelRx Pharmaceuticals (ACRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ONEOK (OKE) Tops Q3 EPS by 63c; raises guidance
- Home Federal Bancorp of Louisiana (HFBL) Tops Q3 EPS by 64c
- Ks Bancorp, Inc. (KSBI) Tops Q3 EPS by 258c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
